Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?

Surma, Stanisław; Romańczyk, Monika; Filipiak‬, Krzysztof J.

doi:10.1016/j.ijcrp.2021.200107

Cited by 6 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Further investigations and new data are also required for the approach suggested to promote the reduction of TG associated ASCVD residual risk with omega-3 acids. In this context, we are also awaiting new therapies that may further improve the suggested therapeutic paradigms, including evinacumab [ 69 , 70 ], apabetalone [ 71 ], and obicetrapib [ 72 ].…”

Section: Discussionmentioning

confidence: 99%

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)

Banach

Surma

Reiner

et al. 2022

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ inertia, including diabetologists and cardiologists, therapy nonadherence, but also underusage and underdosing of lipid lowering drugs due to unsuitable cardiovascular (CV) risk stratification. In the last several years there is a big debate on the risk stratification of DMT2 patients, with the strong indications that all patients with diabetes should be at least at high cardiovascular disease (CVD) risk. Moreover, we have finally lipid lowering drugs, that not only allow for the effective reduction of LDL-C and do not increase the risk of new onset diabetes (NOD), and/or glucose impairment; in the opposite, some of them might effectively improve glucose control. One of the most interesting is pitavastatin, which is now available in Europe, with the best metabolic profile within statins (no risk of NOD, improvement of fasting blood glucose, HOMA-IR, HbA1c), bempedoic acid (with the potential for the reduction of NOD risk), innovative therapies—PCSK9 inhibitors and inclisiran with no DMT2 risk increase, and new forthcoming therapies, including apabetalone and obicetrapib—for the latter one with the possibility of even decreasing the number of patients diagnosed with prediabetes and DMT2. Altogether, nowadays we have possibility to individualize lipid lowering therapy in DMT2 patients and increase the number of patients on LDL-C goal without any risk of new onset diabetes and/or diabetes control worsening, and in consequence to reduce the risk of CVD complications due to progression of atherosclerosis in this patients’ group.

show abstract

Section: Discussionmentioning

confidence: 99%

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)

Banach

Surma

Reiner

et al. 2022

Cardiovasc Diabetol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Evinacumab is a fully human monoclonal antibody directed against ANGPTL3. It binds the N-terminal domain of ANGPTL3 and abolishes the inhibition of LPL and EL [55]. Evinacumab demonstrated a dose-dependent reduction in LDL-C, TG, non-HDL-C, HDL-C, total cholesterol, apoB, and Lp(a) levels in a randomized, double-blind, placebo-controlled trial including subjects with moderately elevated LDL-C levels [56].…”

Section: Evinacumabmentioning

confidence: 99%

Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL

et al. 2022

View full text Add to dashboard Cite

Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.

show abstract

“…Evinacumab stands out as a promising therapeutic agent, employing a unique mechanism of action targeting angiopoietinlike 3 (ANGPTL-3) protein [12]. Evinacumab operates as a human monoclonal antibody specifically designed to interfere with the inhibitory effect of ANGPTL-3 on lipoprotein lipase (LPL), thereby enhancing lipid clearance and reducing circulating low-density lipoprotein (LDL) cholesterol levels [13].…”

Section: Introductionmentioning

confidence: 99%

A mini-review of efficacy, safety, and influence of novel evinacumab on familial hypercholesterolemia

Olatunji,

Kokori,

Moradeyo

et al. 2024

Egypt J Intern Med

View full text Add to dashboard Cite

Background Familial hypercholesterolemia (FH) poses a substantial risk of cardiovascular diseases. The recent approval of evinacumab signifies a breakthrough in FH management. This review synthesizes evidence from diverse clinical trials, examining evinacumab’s efficacy, safety, and broader impact on hypercholesterolemia. Body As highlighted by multiple trials, Evinacumab demonstrates robust efficacy in reducing LDL-C levels, particularly in refractory cases. Its sustained impact, evidenced by enduring reductions in LDL-C levels throughout extended treatment periods, positions it as a potential long-term solution. While the safety profile appears favorable, instances of deaths underline the importance of holistic clinical management and ongoing surveillance. The clinical implications are profound, suggesting evinacumab’s potential inclusion in guidelines for managing severe lipid disorders. Conclusion Future research directions emphasize inclusivity, diversity, and real-world applications to establish sustained efficacy and safety across diverse populations. Integrating evinacumab into clinical guidelines requires evidence-based recommendations, necessitating collaboration between researchers, clinicians, and guideline developers.

show abstract

Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?

Cited by 6 publications

References 11 publications

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)

Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)

Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL

A mini-review of efficacy, safety, and influence of novel evinacumab on familial hypercholesterolemia

Contact Info

Product

Resources

About